rifampicin/isoniazid/ethambutol / Generic mfg. - LARVOL DELTA

Lymphoproliferative Disease Masked as an Anti-Tuberculosis Drug Induced Pancytopenia (APSR 2025) - "He was started on anti-TB with fixed dose combination of rifampicin, isoniazid, ethambutol and pyrazinamide appropriate to his weight as intensive phase of treatment...His anti-TB medications were stopped and bridged with Streptomycin (S), Ethambutol (E) and Moxifloxacin (M), but there was no improvement of blood counts...Anti-TB medications can affect any of the three cell lines separately or in combination. A comprehensive and thorough investigation is required to rule out other diseases before diagnosing anti-TB induced pancytopenia."

Anorexia • Cough • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Respiratory Diseases • Tuberculosis • Waldenstrom Macroglobulinemia

A rare case of eruptive keratoacanthomas associated with antituberculosis treatment HREZ (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide) (WCD 2023) - "The aetiology of eruptive keratoacanthomas remain unclear but they have been linked to immunosuppression, trauma, underlying dermatological conditions like psoriasis, ultraviolet radiations, and use of certain medications (leflunomide, sorafenib, cyclosporine, dabrafenib, vemurafenib and Pembrolizumab)...Acitretin was started in same instance however self-stopped by the patient very shortly after commencement...Based on the only case report available in earlier literature, isoniazid is more likely but not certain to be the responsible agent among HREZ. Isoniazid is a highly specific antibiotic used in treatment of tuberculosis by inhibiting mycolic acid synthesis in cell walls of mycobacterium"

Clinical • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Mood Disorders • Oncology • Pruritus • Psoriasis • Pulmonary Disease • Respiratory Diseases • Squamous Cell Carcinoma • Tuberculosis

Utility of the provocation coupled with the drug reintroduction test in the diagnosis of a hypersensitivity reaction to fixed-dose combination (FDC) of anti-TB drugs (ERS 2022) - "Provocation test coupled with drug reintroduction test of the single-drug formulation in a hospital diagnosed hypersensitivity reaction in all cases and identified the responsible molecule which were Pyrazinamide, Rifampicin, Isoniazid, and Ethambutol in 35%, 11.7%, 5% and 3.3% of cases respectively. Conclusion : Diagnosis tests for a hypersensitivity reaction to FDC of anti-TB drugs are codified. In the absence of drug atopy tests, provocation coupled with reintroduction test find are usefull for the diagnosis of the incriminated molecule."

Allergy • Immunology